Paul Jan Bröckelmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paul Jan Bröckelmann has a total of 434 co-authors. Here are the top co-authors by number of shared publications:
- Bastian von Tresckow
Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer Consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
18 shared publications Peter Borchmann
Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, and German Hodgkin Study Group, Cologne, Germany
14 shared publications- Wolfram Klapper
Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
11 shared publications Andreas Engert
German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany
10 shared publications- Carsten Kobe
Department of Nuclear Medicine Faculty of Medicine and University Hospital Cologne University of Cologne Cologne Germany
10 shared publications Bastian von Tresckow
Department I of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne University of Cologne Cologne Germany
7 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Wiley in HemaSphere
- Vol. 10 (10) , e70485
Quality of life with nivolumab and AVD first‐line treatment of Hodgkin lymphoma in the Phase II GHSG NIVAHL trial
- 29 September 2026
- Published by Wiley in HemaSphere
- Vol. 10 (10) , e70485
Open AccessQuality of life with nivolumab and AVD first‐line treatment of Hodgkin lymphoma in the Phase II GHSG NIVAHL trial
- Open Access
- 21 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (5) , 2094-2102
BrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma
Summary: Intensive multiagent treatment regimens have substantially improved outcomes in advanced‐stage classic Hodgkin lymphoma (cHL). Brentuximab vedotin (BV), etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (BrECADD) demonstrated the highest efficacy in cHL reported to date in a randomised phase III trial. Cytotoxic agents are conventionally administered during the first 4 days of a 21‐day cycle. A total of four cycles are applied to patients with a complete response after two cycles, otherwise six cycles. We developed a condensed BrECADD protocol, reducing intravenous administration days to only three (−25%). Between January 2024 and July 2026, 30 patients received 132 cycles of 3‐day BrECADD at our institution. Primary objective was to describe feasibility and safety; secondary objectives included response, progression‐free survival (PFS) and overall survival (OS). Grade ≥3 adverse events occurred in 23 patients (77%), predominantly haematological. Six patients (20%) had grade ≥3 infections (four viral, two bacterial) and six (20%) had pathogen‐unspecified febrile neutropenia. Twenty‐four patients (80%) required only four BrECADD cycles. There were no treatment discontinuations. After a median follow‐up of 18 months (range 4–29), 1‐year PFS and OS rates were both 100%. Based on these encouraging results, the condensed 3‐day protocol is considered feasible and we recommend it for future BrECADD use.
- 21 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (5) , 2094-2102
Open AccessBrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma
Summary: Intensive multiagent treatment regimens have substantially improved outcomes in advanced‐stage classic Hodgkin lymphoma (cHL). Brentuximab vedotin (BV), etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (BrECADD) demonstrated the highest efficacy in cHL reported to date in a randomised phase III trial. Cytotoxic agents are conventionally administered during the first 4 days of a 21‐day cycle. A total of four cycles are applied to patients with a complete response after two cycles, otherwise six cycles. We developed a condensed BrECADD protocol, reducing intravenous administration days to only three (−25%). Between January 2024 and July 2026, 30 patients received 132 cycles of 3‐day BrECADD at our institution. Primary objective was to describe feasibility and safety; secondary objectives included response, progression‐free survival (PFS) and overall survival (OS). Grade ≥3 adverse events occurred in 23 patients (77%), predominantly haematological. Six patients (20%) had grade ≥3 infections (four viral, two bacterial) and six (20%) had pathogen‐unspecified febrile neutropenia. Twenty‐four patients (80%) required only four BrECADD cycles. There were no treatment discontinuations. After a median follow‐up of 18 months (range 4–29), 1‐year PFS and OS rates were both 100%. Based on these encouraging results, the condensed 3‐day protocol is considered feasible and we recommend it for future BrECADD use.
- 18 June 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (25) , 3118-3121
Gonadal function and fertility after Hodgkin lymphoma treatment with nivolumab-AVD in the phase 2 GHSG NIVAHL trial
In 82 patients with classic Hodgkin lymphoma, stable gonadal hormone levels were observed up to 24 months after nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) first-line treatment. These findings suggest preserved gonadal function and fertility after 4×N-AVD. The trial was registered at www.clinicaltrials.gov as NCT03004833.
- 18 June 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (25) , 3118-3121
Gonadal function and fertility after Hodgkin lymphoma treatment with nivolumab-AVD in the phase 2 GHSG NIVAHL trial
In 82 patients with classic Hodgkin lymphoma, stable gonadal hormone levels were observed up to 24 months after nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) first-line treatment. These findings suggest preserved gonadal function and fertility after 4×N-AVD. The trial was registered at www.clinicaltrials.gov as NCT03004833.
- Open Access
- 10 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (16) , 5492-5495
Brentuximab Vedotin after AlloSCT for Relapsed/Refractory Hodgkin Lymphoma: GHSG BV-ALLO Phase II Trial
- 10 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (16) , 5492-5495
Open AccessBrentuximab Vedotin after AlloSCT for Relapsed/Refractory Hodgkin Lymphoma: GHSG BV-ALLO Phase II Trial
- 30 March 2026
- Published by Springer Nature in Die Onkologie
- Vol. 32 (8) , 1-7
PD1-Inhibition beim klassischen Hodgkin-Lymphom
- 30 March 2026
- Published by Springer Nature in Die Onkologie
- Vol. 32 (8) , 1-7
PD1-Inhibition beim klassischen Hodgkin-Lymphom
- Open Access
- 16 March 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (6) , 2065-2069
Rapid molecular response kinetics to anti-PD-1–based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial
- 16 March 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (6) , 2065-2069
Open AccessRapid molecular response kinetics to anti-PD-1–based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial
- Open Access
- 28 January 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1)
Use and reporting of patient-reported outcomes in randomized controlled trials in non-Hodgkin lymphoma: a scoping review
Background: Non-Hodgkin lymphoma (NHL) constitutes a biologically and clinically heterogeneous group of lymphoid malignancies, with varying prognoses and treatment aims between indolent and aggressive subtypes. While survival outcomes remain key efficacy measures, they insufficiently capture the impact of disease and treatment on daily physical and psychosocial functioning, as well as quality of life (QoL). Objectives: To characterize the use and reporting of patient-reported outcomes (PROs) in adult NHL randomized controlled trials (RCTs), including the trajectory of PRO dissemination throughout the trial reporting process. Methods: MEDLINE, CENTRAL, ClinicalTrials.gov, and WHO ICTRP were systematically searched from 1 January 2017 to 19 January 2023 for NHL RCTs irrespective of subtype, with databases being re-searched until 4 February 2025. Cross-sectional and longitudinal descriptive analyses were conducted to investigate PRO use and reporting practices. Findings: 549 completed and ongoing RCTs met the eligibility criteria, of which 176 trials (32.1%) included a reference to PROs, and 27 (4.9%) used a PRO as a primary outcome. Overall, 95 PRO measures were identified across trials, with EORTC QLQ-C30, FACT-Lymphoma, and EQ-5D being referenced most frequently. Among trials with published results that pre-specified PROs, 25.0% entirely and 10.5% partly omitted PRO findings from their main full-texts, without addressing this shortcoming in subsequent publications. Conclusion: PROs are underused and underreported in RCTs in NHL. Standardized PRO evaluation methodology and guidance for the selection of fit-for-purpose PRO measures are needed, along with clear positioning of PROs alongside survival outcomes in clinical trial design and interpretation.
- 28 January 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1)
Open AccessUse and reporting of patient-reported outcomes in randomized controlled trials in non-Hodgkin lymphoma: a scoping review
Background: Non-Hodgkin lymphoma (NHL) constitutes a biologically and clinically heterogeneous group of lymphoid malignancies, with varying prognoses and treatment aims between indolent and aggressive subtypes. While survival outcomes remain key efficacy measures, they insufficiently capture the impact of disease and treatment on daily physical and psychosocial functioning, as well as quality of life (QoL). Objectives: To characterize the use and reporting of patient-reported outcomes (PROs) in adult NHL randomized controlled trials (RCTs), including the trajectory of PRO dissemination throughout the trial reporting process. Methods: MEDLINE, CENTRAL, ClinicalTrials.gov, and WHO ICTRP were systematically searched from 1 January 2017 to 19 January 2023 for NHL RCTs irrespective of subtype, with databases being re-searched until 4 February 2025. Cross-sectional and longitudinal descriptive analyses were conducted to investigate PRO use and reporting practices. Findings: 549 completed and ongoing RCTs met the eligibility criteria, of which 176 trials (32.1%) included a reference to PROs, and 27 (4.9%) used a PRO as a primary outcome. Overall, 95 PRO measures were identified across trials, with EORTC QLQ-C30, FACT-Lymphoma, and EQ-5D being referenced most frequently. Among trials with published results that pre-specified PROs, 25.0% entirely and 10.5% partly omitted PRO findings from their main full-texts, without addressing this shortcoming in subsequent publications. Conclusion: PROs are underused and underreported in RCTs in NHL. Standardized PRO evaluation methodology and guidance for the selection of fit-for-purpose PRO measures are needed, along with clear positioning of PROs alongside survival outcomes in clinical trial design and interpretation.
- Open Access
- 26 January 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (3) , 666-670
Establishment and characterization of a CCND1-rearranged non-mantle cell lymphoma cell line and patient-derived xenograft model
- 26 January 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (3) , 666-670
Open AccessEstablishment and characterization of a CCND1-rearranged non-mantle cell lymphoma cell line and patient-derived xenograft model
- 31 December 2025
- Published by Springer Nature
- p. 1-8
Antineoplastische Immuntherapie
- 25 December 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (26) , 3145-3152
Feasibility and safety of anti-PD1 first-line treatment of classic Hodgkin lymphoma: do we see the full picture?
Classic Hodgkin lymphoma (cHL) is highly curable with risk-adapted first-line treatment. Due to exceptional efficacy, antiprogrammed cell death protein 1 antibodies (aPD1) are increasingly incorporated into first-line treatment. However, the short- and long-term immune-related adverse event burden in this setting is insufficiently understood. Here, we review the currently available evidence on the feasibility and safety of aPD1 first-line cHL treatment. A more harmonized and complete reporting is critical to enable a detailed understanding and comprehensive assessment of aPD1-related morbidity.
- 25 December 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (26) , 3145-3152
Feasibility and safety of anti-PD1 first-line treatment of classic Hodgkin lymphoma: do we see the full picture?
Classic Hodgkin lymphoma (cHL) is highly curable with risk-adapted first-line treatment. Due to exceptional efficacy, antiprogrammed cell death protein 1 antibodies (aPD1) are increasingly incorporated into first-line treatment. However, the short- and long-term immune-related adverse event burden in this setting is insufficiently understood. Here, we review the currently available evidence on the feasibility and safety of aPD1 first-line cHL treatment. A more harmonized and complete reporting is critical to enable a detailed understanding and comprehensive assessment of aPD1-related morbidity.